VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

WCM/EADO 2021 | Triple therapy for melanoma

Reinhard Dummer, MD, PhD, University Hospital Zürich, Zürich, Switzerland, comments on triple therapies used in melanoma. Phase I clinical investigations of immune checkpoint inhibitors in combination with BRAF and MERK inhibitors indicate promising outcomes, however, some Phase III studies of other combinations have presented conflicting results. While the combination of atezolizumab plus cobimetinib and vemurafenib showed a significant increase in progression-free survival (PFS), treatment with spartalizumab plus dabrafenib and trametinib did not demonstrate an increase in PFS. Prof. Dummer also highlights the importance of understanding differences in patient populations to guide treatment decisions. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter